Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

NCT04047862 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04047862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04047862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Completed
Start date
August 15, 2019
Completion date
August 7, 2024
Enrollment
446 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced and metastatic solid tumors